Sector News

Roche pens $1.9B deal to buy oncology data firm Flatiron

February 19, 2018
Life sciences

Roche has struck a $1.9 billion deal to acquire Flatiron Health. The takeover gives Roche ownership of the cancer software and real-world evidence that turned Google Ventures-backed Flatiron into a rising star.

Flatiron built its business around oncology-focused electronic health record (EHR) software and a repository of real-world cancer evidence. The software has gained traction and given Flatiron links to more than 250 community oncology practices, a network that could prove useful to Roche’s clinical trial unit. But the Big Pharma pointed to the real-world evidence as a key driver of the deal.

“This is an important step in our personalized healthcare strategy for Roche, as we believe that regulatory-grade real-world evidence is a key ingredient to accelerate the development of, and access to, new cancer treatments,” Daniel O’Day, CEO of Roche Pharmaceuticals, said in a statement.

The takeover is reward for the work Flatiron put in to build its real-world evidence repository. Data are plentiful in modern healthcare, but lots of data are held in free text fields or PDF documents, making the information tough to analyze. Flatiron set itself apart by pulling data out of these hard-to-access sources and using them to build high-quality curated repositories. Although healthcare data are plentiful, data sets of that standard are rare—and valuable.

Flatiron was gearing up to add to its more than $300 million in VC funding when the idea of selling up gained pace. Nat Turner, one of the two ex-Googlers who founded Flatiron, told Forbes the shift in strategy followed the realization that cash wasn’t the main bottleneck on the business. What Flatiron needed was resources, specifically a global footprint. Roche can provide that.

Importantly, the Swiss pharma is allowing Flatiron to continue as a separate legal entity that will continue to provide services to the rest of the healthcare industry.

“We’re going to continue to work with everybody, which was very important for us. Hopefully it means not much change. It just means a bigger platform for us,” Turner said.

By Nick Paul Taylor

Source: Fierce Biotech

comments closed

Related News

January 15, 2022

Colorcon Ventures invests in AI-Driven bio-simulation company VeriSIM Life

Life sciences

Colorcon Ventures, the corporate venture fund of Colorcon Inc., has invested in VeriSIM Life, a San Francisco-based startup with a digital bio-simulation platform that accelerates drug development and reduces animal testing.

January 15, 2022

A record number of biotechs are going public. Here’s how they’re performing.

Life sciences

Initial public offerings have fueled biotech’s boom. Keep track of them as they happen with this database. Which biotechs create value over time, and which fail? What types of companies are generating the best returns? Who are their top investors? Biopharma Dive is tracking these details in the database which will be updated regularly.

January 15, 2022

Sanofi cuts ties with Sangamo, sharpening focus on ‘off-the-shelf’ cell therapy

Life sciences

Sanofi has ended a long-running alliance with Sangamo Therapeutics to develop genetic medicines for inherited blood disorders, among them an experimental sickle cell disease therapy that is in early clinical testing.
The two have been developing complex, personalized treatments, led by a sickle cell drug known as SAR445136. But Sanofi is now more interested in off-the-shelf approaches, which are meant to be more convenient.

Send this to a friend